Objetivo de Aprendizaje:

• Incrementar el conocimiento con respecto a los criterios diagnósticos de Enfermedad de Gaucher.
• Incrementar el conocimiento sobre los análisis moleculares para establecer el diagnóstico de Enfermedad de Gaucher.

Referencias:

1. Breiden B, et al. Lysosomal Glycosphingolipid Storage Diseases. Annu Rev Biochem. 2019 Jun 20;88:461-485. https://www.annualreviews.org/deliver/fulltext/biochem/88/1/annurev-biochem-013118-111518.pdf?itemId=/content/journals/10.1146/annurev-biochem-013118-111518&mimeType=application/pdfv
2. Do J, et al. Glucocerebrosidase and its relevance to Parkinson disease. Molecular Neurodegeneration 2019. Aug 29;14(1):36. https://pmc.ncbi.nlm.nih.gov/articles/PMC6716912/
3. Ferraz MJ, et al. Gaucher Disease and Fabry Disease: New Markers and Insights in Pathophysiology for Two Distinct Glycosphingolipidoses. Biochim Biophys Acta 2014 May;1841(5):811-25. https://www.sciencedirect.com/science/article/abs/pii/S1388198113002461?via%3Dihub
4. Mehta A, et al. Presenting signs and patient co‐variables in Gaucher disease: outcome of the Gaucher Earlier Diagnosis Consensus (GED‐C) Delphi initiative. Intern Med J. 2019 May; 49(5): 578–591. https://pmc.ncbi.nlm.nih.gov/articles/PMC6852187/
   Murugesan V, et al. Glucosylsphingosine is a key Biomarker of Gaucher Disease. Am J Hematol. 2016 Nov; 91(11): 1082–1089. https://pmc.ncbi.nlm.nih.gov/articles/PMC5234703/
5. Gelb MH, et al. Direct multiplex assay of enzymes in dried blood spots by tandem mass spectrometry for the newborn screening of lysosomal storage disorders. J Inherit Metab Dis. 2006; 29(2-3): 397–404. https://pmc.ncbi.nlm.nih.gov/articles/PMC2488386/
6. Elmonem MA, et al. Immunomodulatory Effects of Chitotriosidase Enzyme. Enzyme Res 2016; 2016: 2682680. https://pmc.ncbi.nlm.nih.gov/articles/PMC4735922/
7. Malaguarnera L. Chitotriosidase: The Yin and Yang. Cell Mol Life Sci. 2006 Dec; 63(24): 3018-29. https://pmc.ncbi.nlm.nih.gov/articles/PMC11136280/
8. Juárez-Rendón KJ, et al. Duplicación 24-pb en el gen CHIT1 en población mexicana. Rev Med Inst Mex Seguro Soc 2012; 50 (4): 375-377. https://www.medigraphic.com/cgi-bin/new/resumen.cgi?IDARTICULO=38686
9. Polo G, et al. Diagnosis of Sphingolipidoses: A New Simultaneous Measurement of Lysosphingolipids by LC-MS/MS. Clin Chem Lab Med. 2017 Mar 1;55(3):403-414. https://www.degruyterbrill.com/document/doi/10.1515/cclm-2016-0340/html
10. Rolfs A, et al. Glucosylsphingosine Is a Highly Sensitive and Specific Biomarker for Primary Diagnostic and Follow-Up Monitoring in Gaucher Disease in a non-Jewish, Caucasian Cohort of Gaucher Disease Patients. PLoS One. 2013; 8(11): e79732. https://pmc.ncbi.nlm.nih.gov/articles/PMC3835853/
11. CENTOGENE Guiding Precision Medicine https://www.centogene.com/
12. Koprivica V, et al. Analysis and classification of 304 mutant alleles in patients with type 1 and type 3 Gaucher disease. Am J Hum Genet. 2000 Jun; 66(6): 1777–1786. https://pmc.ncbi.nlm.nih.gov/articles/PMC1378059/
13. Beutler LE. Identifying Empirically Supported Treatments: What if We Didn’t? J Consult Clin Psychol. 1998 Feb;66(1):113-20. https://psycnet.apa.org/record/1997-38731-007